[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331712-105":59,"doc-detail-331712-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","promising-candidate-drug-target-genes-for-repurposing-in-cervical-cancer-a-bioinformatics-based-approach","Promising candidate drug target genes for repurposing in cervical cancer - A bioinformatics-based approach","","Cervical cancer is a leading cause of cancer mortality among women worldwide, and accumulating evidence links genetic variants to its development. This study applies a bioinformatics workflow to repurpose existing drugs by identifying candidate drug target genes derived from cervical cancer–associated germline and somatic alterations. Genomic integration using GWAS and PheWAS yields 232 related genes, then refines them via six functional annotation thresholds and cross-references results with DrugBank. LTA, TNFRSF1A, PRKCZ, PDE4B, and PARP emerge as promising targets, overlapping with 12 repurposable drugs, especially talazoparib, a PARP inhibitor requiring further clinical validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/promising-candidate-drug-target-genes-for-repurposing-in-cervical-cancer-a-bioinformatics-based-approach/331712/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/promising-candidate-drug-target-genes-for-repurposing-in-cervical-cancer-a-bioinformatics-based-approach/331712.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the study?","Question",{"text":112,"@type":113},"To identify promising drug target genes that could enable repurposed drugs for cervical cancer using a bioinformatics-based approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were candidate genes selected?",{"text":117,"@type":113},"The workflow integrates genomic data using GWAS and PheWAS to obtain 232 cervical cancer–associated genes, then refines them with a biological threshold based on six functional annotations.",{"name":119,"@type":110,"acceptedAnswer":120},"Which repurposed drug candidate is highlighted as especially promising?",{"text":121,"@type":113},"Talazoparib is highlighted due to its role as a potent PARP inhibitor and its overlap with the selected target genes, although it has not yet been studied for cervical cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331712,1791101616,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","distributed under BY-NC 4.0.  \nShort Communication  \nPromising candidate drug target genes for repurposing in cervical cancer: A bioinformatics-based approach  \nNurfi Pratiwi1,2, Aida J. Ulfah1, Rachmadina Rachmadina1, Lalu M. Irham3,4, Arief R. Afief5, Wirawan Adikusuma6,7, Darmawi Darmawi2,8, Rahmat A. Kemal9, Ina F. Rangkuti10 and Maya Savira8,11*  \n1Master Program in Biomedical Sciences, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia; 2Department of Histology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia; 3Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia; 4Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand; 5Faculty of Pharmacy, Universitas YPIB Majalengka, Majalengka, Indonesia; 6Department of Pharmacy, Universitas Muhammadiyah Mataram, Mataram, Indonesia; 7Research Center for Computing, Research Organization for Electronicsand Informatics, National Research and Innovation Agency (BRIN), Cibinong Science Center, Cibinong, Indonesia; 8Graduate School in Biomedical Sciences, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia; 9Department of Medical Biology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia; 10Department of Pathological Anatomy, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia; 11Department of Microbiology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia  \n*[Corresponding author: mayasavira@lecturer.unri.ac.id](Corresponding author: mayasavira@lecturer.unri.ac.id)  \nAbstract  \nCervical cancer is the fourth most common cancer among women globally, and studies have shown that genetic variants play a significant role in its development. A variety of germline and somatic mutations are associated with cervical cancer. However, genomic data derived from these mutations have not been extensively utilized for the development of repurposed drugs for cervical cancer. The objective of this study was to identify novel potential drugs that could be repurposed for cervical cancer treatment through a bioinformatics approach. A comprehensive genomic and bioinformatics database integration strategy was employed to identify potential drug target genes for cervical cancer. Using the GWAS and PheWAS databases, a total of 232 genes associated with cervical cancer were identified. These pharmacological target genes were further refined by applying a biological threshold of six functional annotations. The drug target genes were then cross-referenced with cancer treatment candidates using the DrugBank database. Among the identified genes, LTA, TNFRSF1A, PRKCZ, PDE4B, and PARP were highlighted as promising targets for repurposed drugs. Notably, these five target genes overlapped with 12 drugs that could potentially be repurposed for cervical cancer treatment. Among these, talazoparib, a potent PARP inhibitor, emerged as a particularly promising candidate. Interestingly, talazoparib is currently being investigated for safety and tolerability in other cancers but has not yet been studied in the context of cervical cancer. Further clinical trials are necessary to validate this finding and explore its potential as a repurposed drug for cervical cancer.  \nKeywords: Cervical cancer, drug target genes, bioinformatic, drug candidate, PARP inhibitor  \nIntroduction  \nCervical cancer ranks fourth in terms of incidence and mortality among cancers in women worldwide [1] . As reported by the Global Cancer Observatory (GCO) , there were 341,831 deaths  \nShort Communication  \nPratiwi et al. Narra J 2024; 4 (3): e938-[http://doi.org/10.52225/narra.v4i3.938](http://doi.org/10.52225/narra.v4i3.938)  \nrelated to cervical cancer and 614,127 new cases in 2022 [2] . In 37 countries, mainly situated in sub-Saharan Africa, South America, and Southeast Asia, cervical cancer is the primary cause of cancer-related deaths [1] . Based on the Indonesian Ministry of Health report, cervical cancer is the second most common gynecological cancer among women, with","cbCaidHLzv3wOIOc","https://ap.wps.com/l/cbCaidHLzv3wOIOc","pdf",698485,12,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main objective of the study?\",\"answer\":\"To identify promising drug target genes that could enable repurposed drugs for cervical cancer using a bioinformatics-based approach.\"},{\"question\":\"How were candidate genes selected?\",\"answer\":\"The workflow integrates genomic data using GWAS and PheWAS to obtain 232 cervical cancer–associated genes, then refines them with a biological threshold based on six functional annotations.\"},{\"question\":\"Which repurposed drug candidate is highlighted as especially promising?\",\"answer\":\"Talazoparib is highlighted due to its role as a potent PARP inhibitor and its overlap with the selected target genes, although it has not yet been studied for cervical cancer.\"}]","Promising candidate drug target genes for repurposing in cervical cancer - A bioinformatics-based approach | PDF",1789994804]